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To test the protection afforded by a weakly pathogenic HIV-2 isolate against the superinfection or development of SIV-
induced disease, we intrarectally challenged six HIV-2-preinfected rhesus monkeys with a pathogenic isolate of SIVmac251.
At the time of SIV challenge, none of these HIV-2-infected animals was positive for virus isolation, p27-Gag antigenemia,
or HIV-2 provirus detection in PBMCs or peripheral lymph nodes. However, all monkeys exhibited anti-HIV-2 antibody titers
ranging from 102 to 103. Neutralizing antibodies against the challenge SIV strain were also detected in two animals. After
rectal exposure to SIVmac251, five of the six HIV-2-preinfected macaques were superinfected. SIVmac251 DNA sequences
were detected repeatedly in the PBMCs of the five superinfected animals and the two controls, whereas no HIV-2 provirus
was detected for 14 months postchallenge. The one monkey that resisted superinfection was negative for all SIV infection
criteria. This monkey exhibited the highest anti-SIV ELISA and cross-neutralizing antibody titers on the day of SIV challenge.
Preinfection with a weakly pathogenic HIV-2 ROD isolate protected one of six macaques from infection with the closely
related pathogenic SIVmac251 isolate, but no protection from the progression of disease was evidenced in the other five.
q 1996 Academic Press, Inc.
INTRODUCTION al., 1994, 1991; Stahl-Hennig et al., 1992; Sutjipto et al.,
1990). However, the experiments in which whole inacti-
In spite of the unsuccessful results obtained so far,
vated SIV grown in human cells was used for vaccination
the elaboration of an effective vaccine is today still the
and challenge produced controversial results. Thus, sev-
only hope of circumventing the dramatic worldwide
eral investigations showed that protection against virusspread of HIV infection. New original strategies have to
challenge did not correlate with anti-SIV-specific immu-be assessed, and for this purpose, investigators have at
nity but with the anti-human immunity elicited by cellulartheir disposal relevant primate models of human HIV
antigens which were associated with the virus envelopeinfection and disease. One of these is experimental infec-
and had been incorporated into the inactivated vaccinetion of the macaque with primate lentiviruses such as
preparation (Arthur et al., 1992; Bergmeier et al., 1994;simian immunodeficiency virus (SIV) or HIV-2 (Desrosiers
Cranage et al., 1993; Langlois et al., 1992; Le Grand etet al., 1989; Dormont et al., 1989). SIV is a retrovirus
al., 1992; Mills et al., 1992; Stahl-Hennig et al., 1993; Stott,which is indeed closely related to HIVs, both biologically
1991). Hopes were recently turned toward the use ofand genetically (Chakrabarti et al., 1987; Guyader et al.,
live-attenuated viruses as vaccines. Many recent studies1987); it has the same CD4 molecule as cellular receptor
showed that after subsequent experimental superinfec-and infects T cells as well as monocyte/macrophages.
tion with homologous or heterologous pathogenic vi-In addition, SIV induces chronic infection in macaques
ruses, intravenous infection with a nonpathogenic atten-and some SIV strains generate immunodeficiency
uated virus conferred protection or, at least, prevented(Baskin et al., 1988; Daniel et al., 1985; Desrosiers, 1990;
disease progression (Almond et al., 1995; Daniel et al.,Letvin et al., 1985; McClure et al., 1989). Among the large
1992). Putkonen et al. recently reported that infection ofnumber of SIV and HIV-2 vaccine preparations that have
macaques with a nonpathogenic strain of HIV-2 had abeen tested in nonhuman primates, only the whole inacti-
‘‘vaccine effect’’ against a subsequent intravenous inocu-vated or live-attenuated viruses are able to confer protec-
lation of the heterologous and highly pathogenic SIVsmtion from infection or, at least, from disease progression
strains (Putkonen et al., 1995). The monkeys in their ex-(Desrosiers et al., 1989; Johnson et al., 1992; Marthas et
periments were not in fact protected from SIV infection,al., 1992, 1990; Murphey-Corb et al., 1989; Putkonen et
but the progression of disease was significantly delayed.
To assess the immune efficacy of their strategy against1 To whom reprint requests should be addressed. Fax: (33)-1-46 54
77 26. mucosal infection, we designed a similar experimental
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protocol in which rhesus macaques, chronically infected HIV-2 virus isolation from PBMCs
with HIV-2 ROD for 2 to 6 years (Nicol-Jourdain et al.,
After HIV-2 inoculation, the animals were bled regu-1993), were challenged intrarectally with a pathogenic
larly. Fresh rhPBMCs were separated by standard den-SIVmac251 virus strain obtained from spleen cells of an
sity gradient centrifugation (MLS; Eurobio, Les Ulis,infected monkey and propagated in fresh rhesus periph-
France), washed in phosphate-buffered saline (PBS), anderal blood mononuclear cells (rhPBMCs) (Le Grand et
cocultured with human cord blood mononuclear cellsal., 1992).
(huCBMCs), using 5 1 106 rhPBMCs for 107 huCBMCs.
Human cells were prestimulated for 3 days with 10 mg/
ml phytohemagglutinin-P (Sigma, St. Louis, MO). CellsMATERIALS AND METHODS
were cultured in RPMI 1640 (Boehringer, Mannheim, Ger-
many) supplemented with 10% heat-inactivated fetal calfAnimals
serum (Boehringer), 20 mM L-glutamine (Gibco BRL, NY),
1% triantibiotic solution containing penicillin, streptomy-Eight rhesus monkeys (Macaca mulatta) comprising 1
cin, and neomycin (Gibco BRL), 2 mg/ml polybrenefemale and 7 males were imported from China and
(Sigma), 1007 IU ml01 of anti-recombinant interferon-ahoused in single cages in level 3 biosafety facilities. All
antibodies (Sigma), and 10 IU of human recombinantmacaques were negative for SIV and STLV (simian T
interleukin-2 (IL-2) (Boehringer). Virus production in su-lymphotropic virus) before HIV-2 inoculation. Animals un-
pernatants was evidenced by detecting reverse tran-derwent periodic clinical examination under ketamine
scriptase activity as previously described (Barre´-Sinoussichlorhydrate anesthesia (Rhone-Me´rieux, Lyon, France).
et al., 1983).Blood samples were collected weekly for hematologic,
virologic, and immunologic analysis for 4 weeks after
Detection of circulating infected cells after SIVinoculation with SIV and monthly thereafter. All experi-
challengemental procedures were conducted according to the Eu-
ropean ‘‘Council Directive on the Protection of Animals The assay for detection of infected cells after SIV chal-
Used for Experimental and other Scientific Purposes’’ (86/ lenge was performed using fresh Ficoll-isolated monkey
609/EEC, Journal Officiel des Communaute´s Europe´en- PBMCs. Cocultures were performed using 4 1 106
nes, L358; December 18, 1986). CEMX174 human cells for 2 1 106 rhPBMCs in the stan-
dard culture medium described above but not supple-
mented with IL-2. Virus production was evidenced byViruses
detection of the p27 antigen using an SIV core Ag assay
(Retrovirology Coulter Corporation, Hialeah, FL). For theHIV-2 ROD and EHO isolates were kindly provided by
Professor L. Montagnier (Institut Pasteur, Paris, France) titration of cell-associated virus load, threefold dilutions
of rhPBMCs were cocultivated in triplicate in 96-well flat-and were propagated in vitro only in human peripheral
blood mononuclear cells (huPBMCs). Six rhesus ma- bottomed culture plates (Labware/Falcon, Lincoln Park,
NJ) with 12.5 1 104 CEMX174 cells, in a total volume ofcaques were intravenously and intracerebrally inocu-
lated in 1987 with the HIV-2 ROD or EHO isolates. These 200 ml of culture medium (Le Grand et al., 1994). Cultures
were maintained in a 5% CO2 humidified incubator andanimals were reinoculated in 1989 with the HIV-2 ROD
isolate, after one passage in a macaque that exhibited half of the cell suspension was replaced by fresh culture
medium on Days 3, 5, 7, 9, and 11. On Day 14, microplatesan AIDS-like disease, as previously reported (Dormont
et al., 1989, 1990). Two years before SIV challenge, one were examined under an inverted microscope for syncy-
tium formation, and the cell suspension was lysed withanimal was transfused with 10 ml of whole blood from
one HIV-2-infected monkey. 50 ml of 2.5% Nonidet-P40 detergent solution (Sigma).
For the SIV antigen detection assay, 100 ml of the cellThe pathogenic SIVmac251 cell-free virus stock used
for intrarectal challenge was provided by Dr. A. M. Auber- suspension was used to coat ELISA microplates (Nunc,
Roskilde, Denmark) for 1 night at 377. Plates were thentin (Universite´ Louis Pasteur, Strasbourg, France). This
virus was grown on rhPBMCs without previous passage washed three times with 300 ml of PBS and saturated for
1 hr at 377 with 300 ml of PBS and 5% nonfat milk. Next,in normal or transformed human cells. According to
Spouge (1992), this virus stock contains 2 1 102 50% plates were washed five times with PBS containing 0.1%
Tween 20 (Sigma). The antibody solution for SIV antigenintrarectal animal infectious dose (irAID50) per milliliter
(Le Grand and Dormont, 1993) and 4 1 104 intravenous detection was provided by a pool of inactivated sera from
SIVmac251-infected macaques, diluted 1003 in a solutionAID50 per milliliter (Le Grand et al., 1992). In 1994 all the
HIV-2-seropositive animals and two naive controls were of PBS, 0.1% Tween 20, and 5% milk. Plates were incu-
bated for 2 hr at 377 with this anti-SIV serum and thenchallenged by the rectal route with 10 irAID50 of SIV-
mac251 virus stock. Before SIV inoculation, the animals washed five times as indicated above. Anti-SIV antibod-
ies were detected by 1 hr of incubation with peroxidase-were subjected to 48 hr of hydric diet.
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labeled goat anti-monkey IgG (Organon Teknika, Turn- and 5*-CCAAGTAGAAGTCTGTGTCTCC-3* (nucleotides
7386–7407), respectively. The pol outer and inner up-hout, Belgium) in a solution of PBS, 0.1% Tween 20, and
5% milk. Plates were then washed five times as indicated stream primer pairs designated SPEP and SPIP were 5*-
ATTCCACTTACCAGTTGAGAGG-3* (nucleotides 3988–above and once with PBS alone. Peroxidase activity was
revealed by incubating the plates for 30 min in the dark 4009) and 5*-ACAGTGGTGGACAGACTATTGG-3* (nucle-
otides 4021–4042), respectively. The pol outer and innerin a solution of 0.1% H2O2 , 3 mg/ml orthophenilendiamine
(Sigma) and 0.05 M citrate, pH 5.6. The reaction was downstream primer pairs designated SPEN and SPIN
were 5*-CAGGTGTCTACTATCTGTCTGG-3* (nucleotidesstopped with 50 ml of 4 N H2SO4 solution. The optical
density (OD) of the plates was read at 490 nm (cutoff is 4602–4623) and 5*-GCCTGCTCTCTGATTCTGTAGG-3*
(nucleotides 4352–4373), respectively.the average OD of 12 uninfected control wells of the
same culture microplate / 2.201 SD). Titers of cell-asso- Polymerase chain reaction procedure. The first-round
reaction mixture contained total genomic DNA (1 mg), theciated virus load were determined using the Ka¨rber
method (1931). outer pair of primers (25 pmol each), dNTPs (100 mM
each), 10 ml of Taq polymerase buffer (10 mM Tris–HCl,
p27 antigenemia pH 8.3), 1.5 mM MgCl2 , 50 mM KCl, 0.1% Triton X-100,
and 0.5 units of Taq polymerase (Appligen, Illkirch,
The p27 nucleocapsid protein was detected in undi-
France). Initial denaturation was performed at 947 for 4
luted plasma using the Coulter SIV core Ag assay (Retro-
min. The primers were annealed for 90 sec, at 607 for
virology Coulter Corporation).
all outer primer pairs (HGEP/HGEN, HPEP/HPEN, SEEP/
SEEN and SPEP/SPEN), 637 for HIV-2-specific inner prim-Polymerase chain reaction
ers (HGIP/HGIN), and 607 for SIV-specific inner primers.
The templates were amplified at 727 for 35 cycles. ForPBMCs isolated from macaques were lysed overnight
with proteinase K in a PCR lysis buffer. DNA was ob- the second round of amplification using the inner primer
pairs, 1 ml of the first amplification mixture served astained by the phenol–chloroform extraction method and
1 mg of total DNA was used as template for amplification. template. To assess the validity of the results of each
PCR assay, DNA from HIV-2-infected huPBMCs, DNATwo nested sets of oligonucleotide primers specific for
the env and pol genes of SIVmac251 and two nested from SIV-infected rhPBMCs, and DNA from uninfected
rhPBMCs were used as HIV-2 and SIV positive and nega-sets of oligonucleotide primers specific for the gag and
pol genes of HIV-2 ROD were used. In these oligonucleo- tive controls and were included in each assay. Amplified
products were resolved by 1% agarose gel electrophore-tide sequences of the primer pairs listed below, there is
no cross-reaction between the SIVmac251 and the HIV-2 sis and detected by ethidium bromide staining. The am-
plified DNA sequences were then blotted onto Hybond-ROD strains under the experimental conditions we used.
HIV-2-specific primers. The gag outer and inner up- N membrane for hybridization with 32P-labeled probes.
Oligonucleotidic probes specific for HIV-2 gag, HIV-2 pol,stream primer pairs designated HGEP and HGIP were
5*-GAAGCAGCAGAATGAGATGT-3* (nucleotides 1173– SIV env, and SIV pol were 32P-radiolabeled using the 5*-
end-labeling method and hybridized with the correspond-1192) and 5*-TGACATAGCAGGGACAACAAGC-3* (nucle-
otides 1250–1271), respectively. The gag outer and inner ing PCR product blotted onto the nylon filter.
downstream primer pairs designated HGEN and HGIN Detection of HIV-2- and SIV-specific antibodies
were 5*-TGTCATGGCTTACCACACTT-3* (nucleotides
ELISA. Antibody responses were tested in plasma.1785–1804) and 5*-TAAATGCCTTTCTCTGCTGG-3* (nu-
Anti-HIV-2 serum reactivity was determined using an HIV-cleotides 1694–1713), respectively. The pol outer and
2 antigen detection ELISA (ELAVIA II; Sanofi Diagnosticsinner upstream primer pairs designated HPEP and HPIP
Pasteur, France). Anti-SIV plasma reactivity was deter-were 5*-CAGAGAGAGAGACCATACAAGG-3* (nucleo-
mined using an SIV antigen detection ELISA based ontides 1986–2007) and 5*-ACCAACAGAGGACTTGCTGC-
whole lysate of SIVmac251-infected CEMX174 cells. The3* (nucleotides 2063–2082), respectively. The pol outer
ELISA titer corresponded to the reciprocal of the lastand inner downstream primer pairs designated HPEN
plasma dilution that resulted in significant positive opticaland HPIN were 5*-AGGATTAGTTGGAGGTGCTTCC-3*
density (Le Grand et al., 1992).(nucleotides 2524–2545) and 5*-GTGTCGCCTGTCATT-
Western blot analysis. Specificity against different SIV
ATGGTGG-3* (nucleotides 2301–2322), respectively.
(or HIV-2) proteins was confirmed by Western blot (New-
SIV-specific primers. The env outer and inner upstream
LAV-Blot II; Sanofi-Diagnostics Pasteur). The anti-human
primer pairs designated SEEP and SEIP were 5*-GAG-
IgG in the kit was replaced by goat anti-monkey IgG
AATACAGTCACAGAACAGG-3* (nucleotides 6814–6835)
(Organon Teknika).
and 5*-CAACAATAACAACAGCAGCACC-3* (nucleotides
Virus neutralization assay6962–6983), respectively. The env outer and inner down-
stream primer pairs designated SEEN and SEIN were 5*- In a 96-well flat-bottom culture microplate, serial dilu-
tions (in quadruplicate) of serum to test were incubatedCATTGATTGGTTGTGAGTGG-3* (nucleotides 7575–7594)
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TABLE 1
Virologic and Immunologic Status of HIV-2-Infected Macaques during the 1st Year after the Second Inoculation
with HIV-2 ROD and 5 Years Later on the Day of SIV Challenge
33209 33219 34433 34771 34782 37207a
After Day of After Day of After Day of After Day of After Day of After Day of
HIV-2 SIV HIV-2 SIV HIV-2 SIV HIV-2 SIV HIV-2 SIV HIV-2 SIV
exposure challenge exposure challenge exposure challenge exposure challenge exposure challenge exposure challenge
Anti-HIV-2b ELISA
titer 4 2 4 2 4 2 ND 2 ND 3 ND 2
Anti-SIVb ELISA titer ND 2 ND 2 ND 2.69 ND 2 ND 2 ND 2
Anti-SIVb neutralizing
Ab titer ND 1.69 ND 1.69 ND 2 ND 1.69 ND 1.69 ND 1.69
Virus isolationc / 0 / 0 / 0 / 0 / 0 0
p27 antigen ND 0 ND 0 ND 0 ND 0 ND 0 ND 0
PCR on PBMCd and
LNMC / 0 / 0 / 0 / 0 / 0 ND 0
a Macaque 37207 was transfused with 10 ml of blood from another macaque that had received one inoculation of HIV-2R0D33215 isolate in 1989.
b Values are expressed in log 10 of the last positive dilution. Ab, antibodies.
c Virus isolation from HIV-2-preinoculated macaques was positive at various time points until 10 months after the second HIV-2 inoculation. Virus
was isolated using human PBMCs as target cells in cocultures with simian PBMCs obtained from HIV-2-infected monkeys.
d PCR was done 8 months after the second HIV-2 inoculation on peripheral blood mononuclear cells and on lymph node mononuclear cells(LNMC).
with 10-fold tissue culture 50% infectious doses (TCID50) cules. Cells were then washed three times with 2 ml of
PBS and fixed with 1% paraformaldehyde in PBS. Fre-of the virus stocks for 2 hr at 377, in PBS supplemented
with 10% complement-depleted sera collected from quency of each cell subset was evaluated using a FACS
analyzer (Becton–Dickinson). Labeling of B cells withhealthy and uninfected macaques. Controls were run as
specified above in the absence of serum. The virus stock anti-CD20 monoclonal antibody (Becton–Dickinson), and
of monocytes with anti-CD11b monoclonal antibody (Bec-used was provided by a cell-free supernatant of in vitro-
infected monkey PBMCs. CEMX174 cells (2.51 104) were ton–Dickinson), was also performed in order to confer
quality controls.added to each well. After 1 hr of infection at 377, cell
suspensions were washed three times in PBS and main-
tained in culture medium in a 5% CO2 humidified incuba- RESULTS
tor at 377. On Days 3, 5, 7, 9, and 11 of culture, half
of the cell suspension was replaced with fresh culture Status of monkeys before SIVmac251 challenge
medium. On Days 7 and 14, 100 ml of the cell suspension
The results of macaque inoculation with HIV-2 RODin each well was treated for 30 min at 47 with 20 ml of
have already been published (Dormont et al., 1990; Nicol-2.5% Nonidet-P40 detergent solution and used to coat
Jourdain et al., 1993). Briefly, all six HIV-2 ROD-inoculatedELISA plates (Nunc). An ELISA was performed for the
animals were persistently infected for several years, asdetection of viral antigen production as previously de-
confirmed by virologic and biologic analysis (Table 1). Onscribed by Makoschey et al. (1994). The titer of the virus
the day of SIVmac251 challenge, all six HIV-2-preinfectedalone (TCID50V) and the titer of the virus with the different
animals were negative for virus isolation on humanserum dilutions (TCID50S) were calculated by the Ka¨rber
PBMCs, p27-Gag antigenemia, and DNA sequence de-method. Neutralization was considered to be efficient
tection by PCR in PBMCs and lymph nodes. However,when the TCID50S:TCID50V ratio was 0.1 or less.
anti-HIV-2 antibodies were detected by ELISA in all ani-
mals with titers ranging from 102 to 103 (Table 1). On thatCirculating T lymphocyte subset determination
day, only two macaques, 34433 and 33209, exhibited anti-
SIV neutralizing antibodies with titers of 102 and 101.69,Variations in absolute counts of T lymphocyte subsets
were monitored during the investigation period by direct respectively.
On the day of SIV challenge, immunoblot analysisimmunofluorescence assay using either whole blood as
described previously (Benveniste et al., 1996) or Ficoll- showed that plasma samples from four of the six animals
challenged, including those with anti-SIV neutralizing an-isolated monkey PBMCs. Briefly, 5 1 105 freshly isolated
or cryopreserved PBMCs were incubated for 30 min at tibodies, were reactive against the gp105-Env antigen.
Five of six macaques exhibited anti-p27-Gag antibodies.47 with anti-Leu 3a-PE or anti-Leu 2a-FITC monoclonal
antibodies (Becton–Dickinson, Mountain View, CA), re- Plasma of monkey 37207 was reactive only with p27-
Gag antigen. On the day of challenge, no reactivity wasspectively specific for CD4 or CD8 cell surface mole-
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detected in the plasma of monkey 34771 against any Five of the six superinfected animals and both controls
exhibited high cell-associated virus loads ranging fromviral antigen by immunoblot analysis, despite its positive
reactivity by ELISA, which is a more sensitive assay. 281 to 584 TCID50 ; these loads peaked between the 2nd
and 3rd weeks p.c. (Table 3).
Outcome of the SIVmac251 intrarectal challenge Viral antigenemia. Transient plasma p27-Gag antigen-
emia was detected in the control animals and in four ofClinical observations. Two monkeys (33219 and 34782)
developed clinical and biological signs of immunosup- the six HIV-2-preinfected monkeys within the 2nd week
after SIV challenge. In three of these four macaques,pressive disease: skin rash, weight loss, and wasting
syndrome. Monkey 34782 died from disease by Week 14 p27-Gag antigenemia peaked within 2 or 3 weeks p.c.
and thereafter dropped and became transiently negativeafter SIV challenge. Another superinfected animal
(37207) died of disease unrelated to immunosuppres- or weakly positive during the chronic infection period
(data not shown). The fourth animal (34782) remainedsion. Like the HIV-2-preinfected macaques, the two con-
trol animals inoculated with SIV also exhibited weight persistently p27-Gag-positive until death 14 weeks p.c.
In contrast, no p27-Gag antigen was detected in theloss and wasting syndrome.
Circulating T lymphocyte subset determination. In plasma of preinfected animals 34433 and 37207 during
the investigation period. In the naive controls, the antigenfour of six HIV-2-preinfected macaques, circulating
CD4-positive cell counts dropped significantly during level was two to five times higher than in preinfected
animals.acute infection after the SIV challenge. Thereafter, dur-
ing the chronic infection period, these counts dropped Viral DNA detection in PBMCs. The presence of SIV-
mac251 provirus in the circulating PBMCs of challengedprogressively in the five superinfected animals. In mon-
key 34433 which had a low CD4/ count before the macaques was confirmed by qualitative nested PCR
(data not shown). Five of the six superinfected animalschallenge, no significant decrease was seen in circulat-
ing CD4-positive cell count. In the two controls, the and the naive controls were PCR positive for both env
and pol SIV-specific primer pairs within 2 weeks p.c. Nototal number of circulating CD4/ cells also dropped
significantly (Table 2). SIV-specific DNA was detected in the PBMCs of ma-
caque 34433 over the 14 months of follow-up. This mon-Antibodies to viral antigens. Plasma samples were
tested for antibody reactivity. The response to virus chal- key was then euthanized and no SIV or HIV-2 provirus
was detected in its peripheral lymph nodes, spleen, orlenge of the HIV-2-preinfected macaques differed from
the response of the naive controls as regards antibody PBMCs. HIV-2-specific primer pairs chosen in the gag
and pol genes were also tested, in an attempt to evidenceprofiles. In HIV-2-preinfected animals, anti-SIV antibody
titration by ELISA showed that five of the six macaques any resurgence of HIV-2 provirus in SIV-infected animals.
No HIV-2-specific DNA was detected in the PBMCs ofdeveloped an anamnestic response against viral anti-
gens by the 2nd week after SIV inoculation (Fig. 1A). any of the superinfected macaques during the follow-up
period. Hybridization of amplified DNA fragments withBy contrast, in the controls, antibodies were only first
detected by ELISA 4 weeks after SIV exposure, and there- 32P-labeled probes specific to either SIV or HIV-2 also
showed that the DNA sequences detected in PBMCsafter exhibited a gradual increase in titers for 3 months
(Fig. 1B). We failed to detect any enhancement in the from challenged animals were SIV-specific.
plasma antibody response of HIV-2-preinfected monkey
34433 after SIV challenge. Western blot analysis showed DISCUSSION
that antibodies directed against the gp140-Env precursor
were not detectable on the day of SIV inoculation. In HIV- Five of the six HIV-2-preinfected macaques included
in our study belonged to a group of 9 macaques that2-preinfected animals, these antibodies appeared within
4 weeks of challenge. In the naive control monkeys they were intravenously inoculated with HIV-2 ROD or HIV-2
EHO isolates in 1987 (Dormont et al., 1989). Eight monthsappeared later (Fig. 2). At various time points after SIV
inoculation, the plasma from all seropositive animals ex- later, 1 of the animals infected with HIV-2 ROD (33215),
which exhibited evident clinical signs of simian AIDS,hibited strong reactivity to all SIV antigens, especially to
p27-Gag and transmembrane gp36-Env. was euthanized. Twenty months after the first inoculation
of HIV-2, the virus isolated from the macaque 33215Virus isolation from PBMCs. SIV was recovered easily
every week during the 1st month postchallenge (p.c.) in PBMCs was used to reinoculate the surviving animals.
This second intravenous inoculation led to persistent in-five of the six challenged animals and in the two controls
(Table 3). In contrast, no virus could be recovered from fection and a decrease of CD4/ cell counts in all ma-
caques. Two animals subsequently died after developingmonkey 34433, the one which exhibited the highest neu-
tralizing antibody titer on the day of challenge. The virus AIDS-like symptoms 6 months and 5 years after reinocu-
lation (Nicol-Jourdain et al., 1993). Four years after reinoc-was also reisolated from the four surviving superinfected
animals at several time points throughout the 14-month ulation, whole blood from 1 of these animals was trans-
fused to a naive monkey. Transmission of HIV-2 to thisinvestigation period.
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TABLE 2
Evolution of CD4/ and CD8/ Absolute Cell Numbers before and after SIV Challenge in Controls and HIV-2-Preinfected Macaques
HIV-2-preinfected animals Control animals
33209 33219 34433 34771 34782 37207a 49778 49836
Before SIV challenge
Day of first HIV-2 1705b 1572 1595 2005 2121 ND ND ND
inoculation (856)c (831) (938) (768) (1325)
Day of second HIV-2 717 974 577 644 612 ND ND ND
inoculation (1593) (620) (601) (1073) (987)
Weeks after SIV
challenge
0 812 510 469 603 955 787 930 1801
(1057) (173) (258) (720) (792) (572) (645) (2013)
1 1217 751 754 1646 1662 684 1039 930
(1373) (297) (482) (759) (1642) (877) (504) (602)
2 249 326 554 820 254 357 1564 1109
(240) (483) (403) (547) (379) (342) (1556) (1923)
3 459 246 643 1210 120 1079 684 376
(1259) (401) (821) (2132) (1100) (1355) (1579) (2056)
4 561 190 328 327 695 NDd 537 1107
(2325) (295) (437) (1387) (584) (534) (799) (979)
15 367 511 921 1644 582d 860 863
(1105) (795) (681) (2022) (6004) (1112) (1354)
43 402 122 461 76 101 17
(694) (213) (445) (403) (254) (444)
61 153 91 317 256 357 46
(665) (234) (311) (817) (703) (340)
a Macaque 37207 was transfused with 10 ml of blood from another macaque that had received one inoculation of HIV-2ROD33215 isolate in
1989.
b Absulute number of CD4/ lymphocytes per cubic milliliter.
c Values in parentheses are the absolute numbers of CD8/ lymphocytes per cubic milliliter.
d The last measurement before death. Monkey 37207 died 4 weeks after SIV challenge, from SIV-unrelated disease, and monkey 34782, 15 weeks
postchallenge, of an AIDS-like disease.
monkey was confirmed by successful virus isolation from only developed transient SIV viremia, and no evidence
of immunodeficiency was detected for more than 5 yearsits PBMCs and by seroconversion. Three to five years
after HIV-2 reinoculation, the surviving animals remained after challenge, at least in three of the four HIV-2-prein-
fected monkeys. Conversely, naive controls developedhealthy and were negative for p27-Gag antigenemia, HIV-
2 provirus detection in PBMCs and lymph node cells, persistent SIV viremia and died within 8 to 38 weeks of
SIV inoculation. The above authors therefore concludedand HIV-2 provirus isolation from PBMCs. However, all
these monkeys were still seropositive, exhibiting anti- that HIV-2 infection had ‘‘vaccinated’’ macaques against
SIV intravenous infection.HIV-2 ELISA titers ranging from 102 to 103. Therefore,
taking all these results together, we may conclude that We designed a similar experiment, in order to assess,
in macaques, the vaccine effect of HIV-2 infection againstHIV-2 inoculation led to chronic infection in these rhesus
monkeys. Nevertheless, this virus strain may be consid- an atraumatic intrarectal challenge with a pathogenic SIV-
mac251 biological isolate. Since in humans, natural HIVered weakly pathogenic, because during an observation
period exceeding 6 years, AIDS was only observed in 3 of infection mainly occurs by sexual transmission, a vaccine
strategy should induce not only a good anti-viral systemicthe 10 inoculated monkeys. These results are concordant
with those published by others who observed few or no response but also effective mucosal immunity. In our exper-
iment, intrarectal exposure to SIVmac251 establishedevident clinical signs of AIDS in cynomolgus or rhesus
macaques chronically infected with HIV-2 SBL isolate chronic superinfection in five of the six HIV-2-preinfected
rhesus macaques, as confirmed: (1) by the induction of an(Putkonen et al., 1990) or Ben isolate (Petry et al., 1995;
Stahl-Hennig et al., 1990). anamnestic antibody response, (2) by SIV isolation in the
coculture of PBMCs, and (3) by SIV provirus detection inPutkonen et al. recently reported that HIV-2-prein-
fected cynomolgus macaques could be intravenously su- PBMCs. No significant differences were observed between
the cell-associated virus loads of HIV-2-preinfected animalsperinfected with a pathogenic strain of SIV (Putkonen et
al., 1995). However, in their experiments, the animals and controls. Using the SIV-specific and HIV-2-specific
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Four of our five superinfected monkeys were positive
for p27-Gag antigenemia. This antigenemia peaked by
the 2nd week after SIV challenge and dropped to weak
values during the chronic infection. p27-Gag antigenemia
was two to five times higher in controls than in HIV-2-
preinfected macaques. On the 2nd week after challenge,
at the time of the peak of p27-Gag antigenemia, antibod-
ies induced by the anamnestic response were at high
titers. These antibodies could react with core antigen and
therefore partially neutralized the in vitro assay, making it
difficult to interpret the differences between the control
and vaccinated groups.
Finally, after challenge with SIV, five of six HIV-2-prein-
fected macaques exhibited a significant decrease in the
circulating CD4/ cell count. Two of these monkeys ex-
hibited clinical symptoms related to simian AIDS and
one of these two animals died. In contrast to the results
reported by Putkonen et al., our findings therefore sug-
gest that our HIV-2-preinfected animals which were not
resistant to SIV rectal challenge were also not protected
from disease progression.
Only one of the animals we challenged (34433) re-
sisted superinfection and remained negative for all SIV
infection criteria for 14 months p.c. Interestingly, on the
day of SIV challenge, this macaque exhibited the highest
anti-HIV-2 and anti-SIV ELISA titers, as well as the high-
est anti-SIVmac251 serum neutralizing activity. Western
blot data showed that plasma from this same macaque
exhibited high reactivity against the gp105-Env, p27-Gag,
and p17-Gag antigens. After SIV challenge, this animal
did not seroconvert to new viral structural proteins, and
its antibody titer, as evaluated by ELISA, did not rise.
Whether antibodies contribute to protection against
lentiviral infection or prevention from disease progres-
sion is still controversial. Whereas in the chimpanzee
model of human HIV-1 infection, several reports have
strongly suggested that antibodies, most of them di-
rected against the V3 loop of gp120, may contribute to
FIG. 1. SIV-specific antibody response by (A) HIV-2 ROD preinfected sterilizing immunity (Berman et al., 1990; Bruck et al.,
and (B) naive control rhesus macaques after intrarectal challenge with
1994, 1992; Girard et al., 1991), no such contribution bySIVmac251. Plasma samples obtained at various time points postchal-
humoral immunity to protection could be concluded fromlenge were tested in duplicate at dilutions ranging from 1001 to 1007.
ELISA titers are expressed as log10 of the reciprocal of the last plasma the SIV or HIV-2 macaque models.
dilution that resulted in a significant positive optical density. Varied vaccine strategies have been implemented in the
SIV–macaque model of human lentiviral infection. From
most of these experiments, including those involving aprimer pairs, we also demonstrated the presence of SIV
large number of animals (Dormont et al., 1995), only vac-provirus at several time points in the PBMCs of the five
cines using ‘‘live attenuated’’ SIV clones, like those deletedsuperinfected animals, whereas no HIV-2 provirus was de-
in the nef region of the genome, seem to confer at leasttected over an investigation period of 14 months after SIV
partial protection against SIV infection, as confirmed bychallenge. Therefore, SIV mucosal superinfection did not
the reduction in the virus load during acute infection andseem to reactivate HIV-2 replication in vivo, contrary to
significant delaying of the development of simian AIDSwhat others previously reported (Petry et al., 1995). We may
(Almond et al., 1995; Daniel et al., 1992; Kieny et al., 1993).therefore conclude that anti-viral immunity induced by HIV-
In none of these experiments could a clear correlation2 infection does not prevent a high virus load during acute
be established between anti-viral-induced immunity andSIV viremia, as demonstrated by other studies using live
protection by neutralizing antibodies or antigen-specificattenuated vaccines (Almond et al., 1995; Daniel et al.,
1992). cytotoxic T cells (Hulskotte et al., 1995).
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FIG. 2. Immunoblot analysis of antibodies to SIVmac251 in controls and HIV-2-preinfected macaques. GP, glycoprotein; P, protein; D, day; PC,
positive control; NC, negative control.
All these assays were designed to assess protection tracks may facilitate virus excretion and therefore dimin-
ish SIV infectivity. Second, as reported for Sendai virusagainst experimental intravenous inoculation of SIV.
However, the results of our experiments suggest that (Mazanec et al., 1992), these complexes may block the
passage of the virus from the apical to the basal pole ofantibodies may interfere with virus mucosal exposure,
because the only animal protected from SIV rectal chal- the epithelial cells, and therefore prevent its contact with
the sensitive and competent virus-replicating mononu-lenge was the one exhibiting the highest anti-SIV hu-
moral activity. As demonstrated for many mucosal patho- clear cells of the lamina propria. Third, these antibodies
may mediate neutralizing activities, and therefore preventgens, antibodies to lentiviral particles may constitute the
first immune barrier, inhibiting virus transmission by dif- the infection of intraepithelial T cells or mucosal macro-
phages. We did not in fact investigate the level of theferent mechanisms. First, the immune complexes formed
by the virus and the antibodies in the lumen of genital antibody response at the mucosal surface in the monkey
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TABLE 3
Cell-Associated Virus Loads in HIV-2-Preinfected Macaques and Controls at Various Time Points after Intrarectal Challenge with SIV
Days post HIV-2-preinfected animals Control animals
SIV
challenge 33209 33219 34433 34771 34782 37207a 49778 49836
0 1b 1 1 1 1 1 1 1
7 1 135 1 22 3 2 65 195
14 45 94 1 281 94 584 281 281
21 405 281 1 584 405 281 94 584
28 65 195 1 65 94c 2c 195 3
208 3 2 1 1 10 7
425 1 7 1 2 2 2
a Macaque 37207 was transfused with 10 ml of blood from one macaque that had received one inoculation of HIV-2 ROD33215 isolate in 1989.
b Values are expressed in TCID50.
c The last measure before death. Monkey 37207 died 4 weeks after SIV challenge, of SIV-unrelated disease, and monkey 34782, 15 weeks
postchallenge, of an AIDS-like disease.
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